Working Paper Article Version 1 This version is not peer-reviewed

Efficient Single Base Editing in Mouse Using Cytosine Base Editor 4

Version 1 : Received: 28 December 2019 / Approved: 30 December 2019 / Online: 30 December 2019 (11:16:30 CET)

How to cite: Adlat, S.; Yang, P.; Chen, Y.; Sah, R.K.; Oo, Z.M.; Myint, M.Z.Z.; Hayel, F.; Bahadar, N.; Al-Azab, M.; Bah, F.B.; Zhang, L.; Zheng, Y.; Feng, X. Efficient Single Base Editing in Mouse Using Cytosine Base Editor 4. Preprints 2019, 2019120396 Adlat, S.; Yang, P.; Chen, Y.; Sah, R.K.; Oo, Z.M.; Myint, M.Z.Z.; Hayel, F.; Bahadar, N.; Al-Azab, M.; Bah, F.B.; Zhang, L.; Zheng, Y.; Feng, X. Efficient Single Base Editing in Mouse Using Cytosine Base Editor 4. Preprints 2019, 2019120396

Abstract

Most human genetic disease arises from point mutations. These genetic diseases can theoretically be corrected by gene therapy but clinic practice is still far from mature. Nearly half of the pathogenic single-nucleotide polymorphisms (SNPs) are caused by G:C>A:T or T:A>C:G base changes. The best current methods to repair these changes are by base editing without footprint using recently developed CRISPR-Cas9 technology by David Liu’s lab. These base editing methods have been confirmed with precision and efficiency in cultured mammalian cells, but it is barely confirmed and the efficiency is still very low. Animal models are important in dissecting pathogenic mechanism for human genetic diseases and efficacy testing of base correction in vivo. Cytidine base editor BE4 is a newly developed version of cytidine base editing system that converts cytidine (C) to uridine (U) in cultured mammalian cells but has not been proven in vivo. In this study, we have tested this system in cells to inactivate GFP gene and in mice by introducing single-base substitution that leads to a stop codon in tyrosinase gene. High percentage albino coat-colored mice were obtained from black coat-colored donor zygotes after pronuclei microinjection. Sequencing results showed that expected base changes were obtained with high precision and efficiency (56.25%). There are no off-targeting events identified in predicted off-target sites. Results confirm BE4 system can work in vivo with high precision and efficacy, and has great potentials in clinic to repair human genetic mutations.

Subject Areas

BE4; CRISPR-Cas9; Tyr; cytosine base editing; mouse model

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.